Roche said on Tuesday that its sales in the third quarter of 2022 slid 6% year on year to 14.7 billion. Sales for the first nine months of the year landed at 47 billion Swiss francs, rising 2% compared to the same period a year earlier.
"Group sales grew 2% despite the expected sharp decline in COVID-19-related products in both divisions in the third quarter. The demand for our newer medicines for multiple sclerosis, hemophilia, spinal muscular atrophy and cancer remains high," CEO Severin Schwan noted.
The pharmaceutical giant also confirmed its outlook for 2022, noting it expects "stable sales or sales growth in the low-single-digit range" and sees core earnings per share growing in the low- to mid-single-digit range.
